Literature DB >> 19557501

Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy.

Florian Clatot1, Géraldine Philippin-Lauridant1, Matthieu-John Ouvrier1, Tony Nakry1, Sophie Laberge-Le-Couteulx2, Cécile Guillemet1, Corinne Veyret1, Emmanuel Blot3.   

Abstract

Leptomeningeal meningitis occurs in approximately 5% of metastatic breast cancers, and there is no standard treatment for this complication. We retrospectively analyzed the clinical data and cerebrospinal fluid of 24 patients treated with high-dose intrathecal methotrexate for breast cancer leptomeningeal meningitis (BLM). Cytologic response (CSF cytology without neoplastic cells after treatment) was observed in 11 patients (46%) and related to survival (P = 0.005). In addition, clinical symptoms improved in all 11 patients who had a cytologic response and in 7 patients (54%) without cytologic response (P = 0.02). The predictive value of cytologic response needs further confirmation. Cytologic response could be helpful in the management of intrathecal chemotherapy in patients with BLM.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19557501     DOI： 10.1007/s11060-009-9940-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  14 in total

1.  The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study.

Authors:  W Boogerd; M J van den Bent; P J Koehler; J J Heimans; J J van der Sande; N K Aaronson; A A M Hart; J Benraadt; Ch J Vecht
Journal:  Eur J Cancer       Date:  2004-12       Impact factor: 9.162

Review 2.  Leptomeningeal metastases from solid malignancy: a review.

Authors:  Sophie Taillibert; Florence Laigle-Donadey; Catherine Chodkiewicz; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

3.  A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.

Authors:  M J Glantz; K A Jaeckle; M C Chamberlain; S Phuphanich; L Recht; L J Swinnen; B Maria; S LaFollette; G B Schumann; B F Cole; S B Howell
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

4.  Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment.

Authors:  W Boogerd; A A Hart; J J van der Sande; E Engelsman
Journal:  Cancer       Date:  1991-03-15       Impact factor: 6.860

5.  Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy.

Authors:  M C Chamberlain; P R Kormanik
Journal:  J Neurooncol       Date:  1997-10       Impact factor: 4.130

6.  Intrathecal chemotherapy in carcinomatous meningitis from breast cancer.

Authors:  Laura Orlando; Giuseppe Curigliano; Marco Colleoni; Nicola Fazio; Franco Nole; Giovanni Martinelli; Saverio Cinieri; Rossella Graffeo; Giulia Peruzzotti; Aron Goldhirsch
Journal:  Anticancer Res       Date:  2002 Sep-Oct       Impact factor: 2.480

7.  Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone.

Authors:  Dae-Young Kim; Keun-Wook Lee; Tak Yun; Sook Ryun Park; Joo Young Jung; Dong-Wan Kim; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang; Noe Kyeong Kim
Journal:  Jpn J Clin Oncol       Date:  2003-12       Impact factor: 3.019

8.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.

Authors:  S A Grossman; D M Finkelstein; J C Ruckdeschel; D L Trump; T Moynihan; D S Ettinger
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

9.  Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.

Authors:  K Fizazi; B Asselain; A Vincent-Salomon; M Jouve; V Dieras; T Palangie; P Beuzeboc; T Dorval; P Pouillart
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

10.  Breast cancer leptomeningeal metastasis--the role of multimodality treatment.

Authors:  Halina Rudnicka; Anna Niwińska; Magdalena Murawska
Journal:  J Neurooncol       Date:  2007-02-20       Impact factor: 4.506
View more
  18 in total

Review 1.  Biology and therapy of neoplastic meningitis.

Authors:  Aaron G Mammoser; Morris D Groves
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

2.  Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.

Authors:  Pedro Pérez Segura; Miguel Gil; Carmen Balañá; Ignacio Chacón; José Muñoz Langa; María Martín; Jordi Bruna
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

3.  Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.

Authors:  Amanda Fitzpatrick; Marjan Iravani; Adam Mills; Lucy Childs; Thanussuyah Alaguthurai; Angela Clifford; Isaac Garcia-Murillas; Steven Van Laere; Luc Dirix; Mark Harries; Alicia Okines; Nicholas C Turner; Syed Haider; Andrew N J Tutt; Clare M Isacke
Journal:  Clin Cancer Res       Date:  2022-03-15       Impact factor: 12.531

4.  A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer.

Authors:  E Le Rhun; S Taillibert; F Zairi; N Kotecki; P Devos; A Mailliez; V Servent; L Vanlemmens; P Vennin; T Boulanger; M C Baranzelli; C André; G Marliot; J L Cazin; F Dubois; R Assaker; J Bonneterre; M C Chamberlain
Journal:  J Neurooncol       Date:  2013-03-01       Impact factor: 4.130

5.  CSF CA 15-3 in breast cancer-related leptomeningeal metastases.

Authors:  Emilie Le Rhun; Andrew Kramar; Sophie Salingue; Marie Girot; Isabelle Rodrigues; Audrey Mailliez; Fahed Zairi; Edgar Bakhache; Yves Marie Robin; Sophie Taillibert; François Dubois; Jacques Bonneterre; Marc C Chamberlain
Journal:  J Neurooncol       Date:  2014-01-28       Impact factor: 4.130

6.  Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature.

Authors:  Andrew Vincent; Glenn Lesser; Doris Brown; Tamara Vern-Gross; Linda Metheny-Barlow; Julia Lawrence; Michael Chan
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

7.  Leptomeningeal metastases in breast cancer.

Authors:  Brian J Scott; Santosh Kesari
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

8.  Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.

Authors:  Priya Kumthekar; Sean A Grimm; Michael J Avram; Virginia Kaklamani; Irene Helenowski; Alfred Rademaker; Mary Cianfrocca; William Gradishar; Jyoti Patel; Mary Mulcahy; Katie McCarthy; Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2013-01-25       Impact factor: 4.130

9.  Chemical meningitis related to intra-CSF liposomal cytarabine.

Authors:  Bénédicte Durand; Fahed Zairi; Thomas Boulanger; Jacques Bonneterre; Laurent Mortier; Emilie Le Rhun
Journal:  CNS Oncol       Date:  2017-10-23

10.  Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery.

Authors:  Andrew J Huang; Karen E Huang; Brandi R Page; Diandra N Ayala-Peacock; John T Lucas; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Michael D Chan
Journal:  J Neurooncol       Date:  2014-07-22       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.